Abstract
In Graves ophthalmopathy, immunotherapy is offering an opportunity of reducing bad outcomes that lead to disfigurement and impairment of vision. These therapies are not perfect; however, we now have a chance to achieve better outcomes. In asthma, immune therapy using passive immunity targeting key proinflammatory cytokine/chemokines and medications of their effects has opened an avenue of research into a safe and durable therapy. Omalizumab appears to be safe and effective in clinical use. In regional pain syndrome, immune mechanisms may be involved in sustaining long-standing pain, and IVIG may moderate pain sensitivity by reducing immune activation.
Copyright © 2012 Elsevier Inc. All rights reserved.
MeSH terms
-
Allergens / immunology
-
Anti-Asthmatic Agents / therapeutic use
-
Antibodies, Anti-Idiotypic / therapeutic use
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antibodies, Monoclonal, Murine-Derived / therapeutic use
-
Antioxidants / therapeutic use
-
Asthma / immunology
-
Asthma / physiopathology
-
Asthma / therapy*
-
Azathioprine / therapeutic use
-
Benzamides
-
Complex Regional Pain Syndromes / immunology
-
Complex Regional Pain Syndromes / therapy*
-
Cyclosporine / therapeutic use
-
Decompression, Surgical
-
Etanercept
-
Glucocorticoids / therapeutic use
-
Graves Ophthalmopathy / diagnosis
-
Graves Ophthalmopathy / immunology
-
Graves Ophthalmopathy / therapy*
-
Humans
-
Imatinib Mesylate
-
Immunoglobulin G / therapeutic use
-
Immunoglobulins, Intravenous / therapeutic use
-
Immunosuppressive Agents / therapeutic use
-
Immunotherapy / methods*
-
Octreotide / therapeutic use
-
Omalizumab
-
Orbit / radiation effects
-
Piperazines / therapeutic use
-
Pyridones / therapeutic use
-
Pyrimidines / therapeutic use
-
Radiotherapy Dosage
-
Receptors, Tumor Necrosis Factor / therapeutic use
-
Risk Factors
-
Rituximab
-
Selenium / therapeutic use
Substances
-
Allergens
-
Anti-Asthmatic Agents
-
Antibodies, Anti-Idiotypic
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Monoclonal, Murine-Derived
-
Antioxidants
-
Benzamides
-
Glucocorticoids
-
Immunoglobulin G
-
Immunoglobulins, Intravenous
-
Immunosuppressive Agents
-
Piperazines
-
Pyridones
-
Pyrimidines
-
Receptors, Tumor Necrosis Factor
-
Omalizumab
-
Rituximab
-
Cyclosporine
-
Imatinib Mesylate
-
pirfenidone
-
Selenium
-
Azathioprine
-
Etanercept
-
Octreotide